Description:
Atriva Therapeutics GmbH is a biopharmaceutical company developing inhibitors for respiratory viral infections. Atriva's lead product, zapnometinib in Phase 2b (ATR-002), is a host-targeting agent that inhibits viral replication in SARS-COV2, influenza, hantavirus, dengue virus and others, and favourably modulates the body's immune response.
Keywords:
Infectious and parasitic diseases / infectiology / parasitology